炎症性肠病患者CXCR1、IL-17的表达及其意义

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (451 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression and significance of CXC chemokine receptor 1 (CXCR1) and interleukin-17 (IL-17) in patients with inflammatory bowel disease (IBD). Methods The clinical data of 80 patients with IBD admitted to Huizhou Third People′s Hospital from January 2016 to December 2017 was analyzed retrospectively, 70 patients with ulcerative colitis (UC group), 10 patients with Crohn′s disease (CD group), and 50 healthy volunteers who underwent colonoscopy at the same time were selected as control group. The expression of IL-17 and CXCR1 mRNA in serum and intestinal mucosa of each group was compared, and the protein expression of CXCR1 in intestinal mucosa of each group was analyzed. The correlation between the expression of IL-17 and CXCR1 mRNA in serum and in intestinal mucosa of patients was analyzed. Results Compared with the control group, the expression of IL-17mRNA in serum of UC group and CD group were higher (all P ＜ 0.05), but there was no significant difference between UC group and CD group (P ＞ 0.05). There was no significant difference in serum CXCR1 mRNA expression between the two groups (P ＞ 0.05). Compared with the control group, the expression of IL-17 and CXCR1 mRNA in intestinal mucosa of UC group and CD group was higher (P ＜ 0.05). The expression of CXCR1 mRNA in intestinal mucosa of UC group was higher than that of CD group (P ＜ 0.05), however, there was no significant difference in IL-17 mRNA expression between the two groups (P ＞ 0.05). Compared with the control group, the protein expression of CXCR1 in intestinal mucosa of UC group and CD group was higher, and the protein expression of CXCR1 in UC group was higher than that in CD group (P ＜ 0.05). Spearman correlation analysis showed that there was a weak correlation between the expression of IL-17 and CXCR1 in serum and intestinal mucosa (P ＜ 0.05). Conclusion The expression levels of CXCR1 mRNA and IL-17 mRNA in serum and intestinal in IBD patients are higher, and there is a positively correlation between the expression of CXCR1 mRNA and IL-17 mRNA in serum and in intestinal mucosa. It is clinically possible to monitor the levels of CXCR1 and IL-17 to better assist in the treatment of IBD.

Key words： Inflammatory bowel disease CXC chemokine receptor 1 Interleukin-17 Expression

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Qinghong MA Songyan ZHOGN Junfeng

Cite this article:

CAI Qinghong MA Songyan ZHOGN Junfeng. Expression and significance of CXCR1 and IL-17 in patients with inflammatory bowel disease[J]. 中国医药导报, 2019, 16(32): 99-102.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I32/99

[1] 钟捷，顾于蓓.炎症性肠病发病机制与诊治新进展[J].内科理论与实践，2017，12（3）：157-158.
[2] 王二龙，单国栋，詹雅珍.中西医结合治疗炎症性肠病疗效及对免疫指标改变的研究分析[J].中华中医药学刊，2016，34（10）：2507-2510.
[3] 朱超慧，李楠，吴凯，等.IL-23/Th17在炎症性肠病发病中的作用及治疗意义研究进展[J].辽宁医学院学报，2016， 37（5）：103-106.
[4] 李为慧，吴正祥.Th17细胞及IL-23在炎症性肠病中的研究进展[J].胃肠病学和肝病学杂志，2012，21（2）：118-122.
[5] 苏婧玲，谢晨曦，范燕云，等.IL-17BR在炎症性肠病中的表达及其临床意义[J].胃肠病学，2018，23（2）：83-87.
[6] 王鑫，孔文霞，李武良，等.炎症性肠病模型大鼠结肠、血液中IL-17及脑内c-fos的表达规律研究[J].临床医学研究与实践，2016，1（26）：1-3.
[7] 池肇春.炎症性肠病发病机制研究进展[J].中国医师进修杂志，2012，35（z2）：4-6.
[8] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见（2012年·广州）[J].中华内科杂志，2012，51（10）：818-831.
[9] Sairenji T，Collins KL，Evans DV. An Update on Inflammatory Bowel Disease [J]. Prim Care，2017，44（4）：673-692.
[10] 袁援.薏苡附子败酱散保留灌肠结合柳氮磺胺吡啶治疗溃疡性结肠炎临床研究[J].国际中医中药杂志，2017， 39（3）：221.
[11] 张瑞芳，陈朝晖，李灿，等.白头翁复方灌肠对溃疡性结肠炎模型大鼠MUC2、IL-6及IL-10的影响[J].成都医学院学报，2018，13（2）：135-141.
[12] 汤井双，徐为.粪菌移植治疗溃疡性结肠炎临床缓解率的影响因素分析[J].北京生物医学工程，2017，36（6）：619-625.
[13] 郭雪坤，胡小玉.炎症性肠病的发病机理与免疫治疗的研究进展[J].生命科学，2017，29（9）：873-882.
[14] Okumura R，Takeda K. Maintenance of gut homeostasis by the mucosal immune system [J]. Proc Jpn Acad Ser B Phys Biol Sci，2016，92（9）：423-435.
[15] 胡梅，钟英强.CC趋化因子受体5与炎症性肠病的研究进展[J].胃肠病学，2015，20（12）：753-756.
[16] Gijsbers K，Van Assche G，Joossens S，et al. CXCR1-binding chemokines in inflammatory bowel diseases：down-regulated IL-8/CXCL8 production by leukocytes in Crohn′s disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue [J]. Eur J Immunol，2004， 34（7）：1992-2000.
[17] Bank S，Andersen PS，Burisch J，et al. Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort [J]. PLoS One，2015， 10（12）：145 302-145 303.
[18] Trivedi PJ，Adams DH. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise [J]. J Crohns Colitis，2018，12（suppl_2）：S641-S652.
[19] 叶小研，钟英强.CC趋化因子受体与炎症性肠病[J].胃肠病学，2014，19（1）：50-53.
[20] 朱锋，王晓兵，刘适，等.CXC趋化因子受体2和白细胞介素-8在炎症性肠病患者中的表达及其意义[J].胃肠病学，2016，21（6）：331-335.
[21] 王慧，肖玲，王高华，等.趋化因子及其受体与抑郁症关系的研究进展[J].医学综述，2018，24（24）：4790-4795.
[22] 张萌，李楠，吴凯，等.IL-17F与溃疡性结肠炎的研究进展[J].中华临床医师杂志：电子版，2014，8（22）：4082-4085.
[23] Verstockt B，Van Assche G，Vermeire S，et al. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease [J]. Expert Opin Biol Ther，2017，17（1）：31-47.